<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768520</url>
  </required_header>
  <id_info>
    <org_study_id>HL_ENTR_302</org_study_id>
    <nct_id>NCT01768520</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Entelon Tab. 150mg in Patients With Osteoarthritis of Knee</brief_title>
  <official_title>For 12 Weeks, the Multi-center, Randomized, Double-blinded, Clinical Study to Evaluate the Efficacy and Safety of Entelon Tab. 150mg Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee (Phase III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is planned to prove Entelon tab. arm is not inferior to Celebrex cap. arm
      in terms of the efficacy and safety through the change of K-WOMAC's total score sum in
      patients with osteoarthritis of knee.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of total sum of K-WOMAC(Korean The Western Ontario and McMaster Universities Arthritis Index)</measure>
    <time_frame>12 weeks from first drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>for the entire study period(12 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Entelon tab. 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celebrex cap.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks</intervention_name>
    <description>morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex
evening : 1 tab. of active Entelon 150mg</description>
    <arm_group_label>Entelon tab. 150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks</intervention_name>
    <description>morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex
evening : 1 tab. of placebo Entelon 150mg</description>
    <arm_group_label>Celebrex cap.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex
evening : 1 tab. of placebo Entelon 150mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. both gender,35 years ≤ age ≤ 75 years

          2. patients with a diagnosis of OA(osteoarthritis) of the knee within 3 months prior to
             study participation, as determined by the American College of Rheumatology clinical
             and radiographic criteria as follows.

               1. knee arthralgia

               2. more than one case among

                    -  50 years or over

                         -  morning stiffness less than 30 min

                              -  friction sound

               3. osteophyte in radiography

          3. Kellgren and Lawrence Scale Grade II~III

          4. total sum of K-WOMAC Scale more than 30

          5. negative results in pregnancy test of urine in screening period

          6. if women in childbearing age, medically reliable contraception or menopause

          7. patients who give written consent of agreement to voluntarily participate in the
             clinical study

          8. patients who can read and understand written instructions

        Exclusion Criteria:

          1. patients whose total sum of K-WOMAC in visit 2 is less than that in visit 1

          2. fibromyalgic, anserine bursitis, infectious arthritis, rheumatoid arthritis,
             ankylosing spondylitis, gout or pseudogout

          3. knee OA with secondary causes including major dysplastic or congenital malformation,
             ochronosis, acromegaly, Hemochromatosis, Wilson's disease or primary
             osteochondromatosis

          4. anatomical malformation, disease of vertebra or other lower extremities or other
             disease of orthopedics which can disturb the evaluation of the target joint

          5. wound, inflammation or avascular necrosis of the target joint or arthroscopy within 6
             months prior to study participation

          6. patients with administration of injectable hyaluronic acid to the target joint within
             6 months prior to study participation

          7. severe ischaemic heart diseases, peripheral artery disease and/or cerebrovascular
             disease, congestive heart failure, active bronchial asthma

          8. medical history of malignant tumor

          9. active peptic ulcer, gastrointestinal tract bleeding or inflammatory bowel disease

         10. hypersensitivity with aspirin, celecoxib, corticosteroid, acetaminophen, sulfonamide
             derivatives or vitis vinifera or intolerance with fructose, glucose or galactose

         11. continuously(1 week or more) oral or intraarticular administration of corticosteroids
             within 12 weeks prior to study participation

         12. pregnant or lactating women

         13. patients who have experience to participate in other clinical trial within 4 weeks
             prior to study participation

         14. ALT, AST and Serum Creatinine ≥ 2×UNL

         15. drug administration after diagnosing as alcoholic or psychical disease

         16. patients whom the investigators judge as improper to participate in this clinical
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Catholic University of Korea, Bucheon St. Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Kyoung-gi do</state>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Sun Park, CRC</last_name>
      <phone>82 32 340 7236</phone>
      <email>solan42@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Su Yon Kim, CRM</last_name>
      <phone>82 2 3489 6167</phone>
      <email>cutty0314@hanlim.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Ki Min, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

